Comparative Pharmacology
Head-to-head clinical analysis: ALESSE versus EVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALESSE versus EVEX.
ALESSE vs EVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Estrogen receptor agonist; binds to and activates nuclear estrogen receptors, leading to gene transcription and cellular effects in target tissues.
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
0.625-1.25 mg orally once daily; or 0.3-0.625 mg vaginally once daily for 21 days with 7 days off.
None Documented
None Documented
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Terminal elimination half-life is 12-24 hours, with a mean of approximately 18 hours. Due to significant enterohepatic recirculation, the half-life may be prolonged in patients with hepatic impairment or when administered with drugs that inhibit recirculation.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Primarily hepatic metabolism with renal excretion of metabolites; approximately 60% of a dose is excreted in urine as conjugates (glucuronides and sulfates) and 30% in feces via biliary elimination. Less than 5% is excreted unchanged in urine.
Category C
Category C
Estrogen/Progestin Combination Contraceptive
Estrogen